SpectraScience Appoints AMG as Exclusive Distributor in Middle East
July 19 2016 - 9:15AM
Marketwired
SpectraScience Appoints AMG as Exclusive Distributor in Middle
East
SAN DIEGO, CA-(Marketwired - Jul 19, 2016) - SpectraScience,
Inc. (OTC PINK: SCIE), a medical device company utilizing light
technologies to detect and diagnose cancers, announced today that
they have signed a distribution agreement with Advanced Medical
German Co. in Kuwait to be their exclusive distributor in the
Middle East.
"We are pleased to be working with the premier distribution
company for gastroenterology in the Middle East," said Michael
Oliver, President and Chief Executive Officer of SpectraScience,
Inc. "We believe that with our innovative products and the sales,
marketing, and distribution acumen of AMG in the Middle East we are
poised to bring a new level of diagnostic capability to clinicians
in colorectal cancer screening."
"Introducing innovative medical devices to our customers that
improve patient outcomes is a hallmark of AMG. We believe the
WavSTAT Optical Biopsy System has the potential to make screening
for colorectal cancer less invasive and safer for patients, faster
and more efficient for clinicians and, overall, less expensive for
the health care system," said Dr. EYAD, President of AMG. "That
combination of factors is attractive in any medical device
market."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that
designs, develops, manufactures and markets spectrophotometry
systems capable of determining whether tissue is normal,
pre-cancerous or cancerous without physically removing tissue from
the body. Protected by more than 30 patents in 28 countries,
covering fundamental elements of the technology, the WavSTAT
Optical Biopsy System uses light to optically scan tissue and
provide the physician with an immediate analysis. With FDA approval
for sale in the U.S. and the CE Mark for the European Union, the
WavSTAT System is the first commercially available product that
incorporates this innovative patent protected technology for
clinical use.
For more information:
Visit the SpectraScience, Inc. website
www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that
involve risks and uncertainties that may cause SpectraScience's
actual results to differ materially from results discussed in
forward-looking statements. Readers are urged to carefully review
and consider the various disclosures made by SpectraScience in this
news release, its most recent Form 10-K and in SpectraScience's
other reports filed with the Securities and Exchange Commission
("SEC") that attempt to advise interested parties of the risks and
factors that may affect SpectraScience's business. These
forward-looking statements are qualified in their entirety by the
cautions and risk factors filed by SpectraScience in its annual
report on Form 10-K and other documents.
Contacts:Media and Investors:SpectraScience, Inc.Lowell
GiffhornCFOPhone: (858) 847-0200 x2019Email:
lgiffhorn@spectrascience.com
SpectraScience (CE) (USOTC:SCIE)
Historical Stock Chart
From Oct 2024 to Nov 2024
SpectraScience (CE) (USOTC:SCIE)
Historical Stock Chart
From Nov 2023 to Nov 2024